



# Pyrukynd in the UAE

*The MoHAP named-patient coordination pathway — indicative 2026*

HEMATOLOGY · PYRUVATE KINASE DEFICIENCY

## The clinical situation

Pyrukynd (mitapivat) is the first disease-modifying therapy for pyruvate kinase (PK) deficiency, FDA-approved for haemolytic anaemia in adults with this rare, inherited chronic haemolytic anaemia caused by PKLR gene mutations that impair erythrocyte glycolysis. Manufactured by Agios Pharmaceuticals, it is a small-molecule PK activator that restores glycolytic function in red blood cells. Delivered as oral tablets twice daily with dose titration over several weeks based on tolerability and haemoglobin response. Carries warnings about acute haemolysis with abrupt interruption or discontinuation.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist confirms PK deficiency diagnosis (PKLR genotype or enzyme activity assay), baseline haemolysis labs, and the clinical rationale for Pyrukynd.
- 2 MoHAP / DoH / DHA named-patient application.** Physician files dossier: clinical letter, patient reference, product details, titration schedule.
- 3 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed specialty wholesale partner.
- 4 Shipment.** Controlled-room-temperature shipment with importer-of-record handling.
- 5 Arrival & titration start.** Treating haematologist initiates and supervises the titration schedule with response monitoring.

### Indicative economics

**Reference US cash-pay range:** USD 300,000–400,000 annualised at US list (Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**7–14 days** from a complete MoHAP application to first dispensed supply, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your haematologist and MoHAP review, keyed to the PK-deficiency rationale. **Logistics.** Controlled-room-temperature shipment with importer-of-record handling. **Concierge case lead.** Named point of contact for family and care team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Pyrukynd × UAE first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/pyrukynd-uae.html](https://reservemed.com/access-guides/pyrukynd-uae.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team